ArticleJournal of clinical laboratory analysis2022
Low levels of serum IL-39 are associated with autoimmune thyroid disease.
Article in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 12 citations in OpenAlex.
- Salivary asprosin, IL-39, IL-40, and IL-1β levels in diabetic patients with periodontitis: A cross-sectional analysis.Clinical oral investigations · 2026Trial
- Evaluation of Serum IL-39 Levels in Patients with Polycystic Ovary Syndrome.Journal of clinical medicine · 2026Article
- Increased synthesis and intestinal expression of IL-39 in patients with inflammatory bowel disease.Immunologic research · 2024Article
- miRNA-1246, HOTAIR, and IL-39 signature as potential diagnostic biomarkers in breast cancer.Non-coding RNA research · 2023Article
- Interleukin-39 is a novel cytokine associated with type 2 diabetes mellitus and positively correlated with body mass index.Endocrinology, diabetes & metabolism · 2023Article
- Low levels of serum IL-39 are associated with autoimmune thyroid disease.Journal of clinical laboratory analysis · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundInterleukin (IL)-39 is a novel member of IL-12 cytokine family, but its role in autoimmune thyroid diseases (AITD) is unclear. The aim of the present study was to determine serum levels of IL-39 in Hashimoto's thyroiditis (HT) and Graves' disease (GD) patients.
methodsA total of 48 patients with HT, 50 patients with GD, and 45 healthy controls (HCs) were recruited for this study. Levels of serum IL-39 were determined by ELISA.
resultsCompared with HC group, levels of serum IL-39 in patients with HT (p < 0.05) and GD (p < 0.01) were drastically reduced. Among patients with HT, serum IL-39 levels had a positive correlation with white blood cell count (WBC) count and free triiodothyronine level. Among patients with GD, the levels of IL-39 in serum were positively correlated with WBC count and C-reactive protein levels.
conclusionsIL-39 may be a new potential predictor for patients with HT and GD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.